Welcome to our dedicated page for Collegium Pharmaceutical SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Collegium Pharmaceutical, Inc. (Nasdaq: COLL) provides access to the company’s official regulatory submissions as a public biopharmaceutical issuer. These documents, filed with the U.S. Securities and Exchange Commission, offer detailed information on Collegium’s financial condition, risk factors, capital structure, and governance as it advances a portfolio of pain management medications and ADHD-focused neuropsychiatry products.
Investors and analysts can use this page to review periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, key products, and risk environment, and present audited or reviewed financial statements. Current reports on Form 8-K, like those cited in recent disclosures, furnish information on material events, including quarterly financial results, earnings presentations, share repurchase authorizations, and other significant corporate actions.
For those examining executive and board matters, proxy statements on Schedule 14A and related filings provide context on governance and compensation policies. Filings related to securities offerings and credit facilities can shed light on how Collegium finances its operations and business development plans, including the use of syndicated credit arrangements and other debt instruments mentioned in company press releases.
In addition, users can monitor beneficial ownership and insider activity through forms such as Form 4, which report transactions in Collegium’s common stock by directors, officers, and certain shareholders. Understanding these filings can help readers interpret how management and insiders interact with COLL shares over time.
On Stock Titan, SEC documents for Collegium are updated as they become available from EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections on product portfolios, non-GAAP metrics, and risk factors, and make it easier to navigate complex disclosures when researching COLL as an investment or analyzing its regulatory history.
Collegium Pharmaceutical, Inc. reported that it has issued full-year 2026 guidance for revenue and adjusted EBITDA. The company disclosed this information in a press release that is furnished as an exhibit and not filed for liability purposes. It also posted a corporate presentation on its website that may be used in discussions with investors, analysts and other stakeholders, and furnished that presentation as a separate exhibit.
The company emphasized that these outlook figures and related commentary are forward-looking statements based on current management expectations and are subject to numerous risks and uncertainties. It highlighted factors such as commercialization performance of its products, market size and acceptance, reimbursement, regulatory developments, litigation, supply, financing needs and intellectual property protection as key risks that could cause actual results to differ materially from the guidance.
Collegium Pharmaceutical (COLL) Form 4: Director John A. Fallon, MD exercised options and sold shares on 11/12/2025. He exercised stock options for 15,000 shares at $16.49 and 19,853 shares at $9.33, then sold 34,853 shares at a weighted average price of $47.2136.
Following these transactions, he directly beneficially owned 64,634 shares. A footnote states the sale occurred in multiple trades between $46.805 and $47.51. The reported options were fully vested and exercisable, and the specific option positions exercised now show 0 remaining.
Collegium Pharmaceutical (COLL) reported an insider transaction by its EVP & Chief Financial Officer. On 11/06/2025, the officer sold 25,142 shares of common stock at a weighted average price of $40.3801 and a separate tranche of 4,858 shares at a weighted average price of $41.2756, totaling 30,000 shares. Following these sales, the officer beneficially owned 126,667 shares, held directly.
The sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 30, 2025, with prices executed across ranges of $40.00–$40.98 and $41.00–$41.75, as disclosed.
Collegium Pharmaceutical (COLL) reported stronger Q3 2025 results. Product revenues, net reached $209,361 (up from $159,301), and net income was $31,507 (vs. $9,335). Gross profit rose to $129,171 with total operating expenses at $67,084. Diluted EPS was $0.84.
For the nine months, product revenues, net were $575,118 (vs. $449,500) and operating cash flow was $206,275. Cash and cash equivalents increased to $150,096, with marketable securities at $135,767. By product in Q3: Belbuca $58,255; Xtampza ER $50,478; Jornay PM $41,802; Nucynta IR $31,988; Nucynta ER $22,813; Symproic $4,025. Jornay PM growth reflects the Ironshore acquisition, which contributed a $635,000 intangible asset now amortizing over 7.7 years.
Debt included term notes payable of $570,166 (carrying value) and convertible senior notes at $237,950. The deferred royalty obligation tied to Jornay PM carried $122,279, with the royalty rate stepping from 7.4% before July 1, 2025 to 9.7% thereafter through March 2032.
Collegium Pharmaceutical (COLL) reported that it released its financial results for the quarter ended September 30, 2025. The company furnished a press release and an earnings presentation alongside this update.
The materials were provided as exhibits to an 8-K: Exhibit 99.1 (press release) and Exhibit 99.2 (earnings presentation). Both exhibits were furnished under Items 2.02 and 7.01. COLL’s common stock trades on the NASDAQ Global Select Market.
Thomas B. Smith, EVP and Chief Medical Officer of Collegium Pharmaceutical, Inc. (COLL) reported the sale of 17,478 shares of the company's common stock on 08/29/2025 at a weighted-average price of $38.4241 per share. After the reported disposition, the reporting person beneficially owned 70,264 shares, held directly. The Form 4 was filed as a single-person report and signed by an attorney-in-fact, Colleen Tupper, on 09/03/2025. The footnote states the reported price is a weighted average for multiple transactions that ranged from $38.37 to $38.48 and that the filer can provide per-price breakdowns on request.
Collegium Pharmaceutical, Inc. (COLL) Form 144 notice: An insider plans to sell 17,478 shares of common stock through Merrill Lynch, with an aggregate market value of $671,576.38. The shares represent vested restricted stock units acquired on 02/21/2025 and were transferred to a brokerage account the same day. The filing lists the approximate sale date as 08/29/2025 and identifies NASDAQ as the exchange. The filer reports no securities sold in the past three months and includes the standard signer representation that no undisclosed material adverse information is known.
Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, Inc. (COLL), reported contemporaneous option exercise and market sale executed under a Rule 10b5-1 trading plan. On 08/18/2025 he exercised a stock option to acquire 16,389 shares at an exercise price of $21.34 per share, and the same day sold 16,389 shares in multiple transactions at a weighted average price of $38.2068, reducing his reported beneficial ownership to 103,613 shares. The option exercised is fully vested and exercisable and expires on 02/05/2030. The Form 4 notes the transactions were effected pursuant to a 10b5-1 plan adopted August 28, 2024, and a power of attorney was used to file the report.
Insider transactions reported for Collegium Pharmaceutical, Inc. (COLL)
Director Gino Santini filed a Form 4 reporting transactions on 08/15/2025. The filing shows acquisition of 15,000 shares of common stock at a price of $13.45 (reported with code M) and a sale of 5,405 shares at a weighted-average price of $37.1912. Following the reported acquisition the filing lists 100,447 shares beneficially owned, and following the sale it lists 95,042 shares beneficially owned. The filing also references a stock option with a $13.45 exercise price related to 15,000 underlying shares and states the option is fully vested and exercisable. The signature on the form is by an attorney-in-fact on 08/19/2025.
Form 144 notice for Collegium Pharmaceutical, Inc. (COLL): An insider filed a proposed sale of 16,389 common shares to be brokered through Fidelity Brokerage Services LLC on 08/18/2025 with an aggregate market value of $626,170.29. The filing reports 31,502,127 shares outstanding and lists the exchange as NASDAQ. The securities reported were acquired under an option granted on 02/05/2020 and are noted as acquired on 08/18/2025, with payment indicated as cash. The filing also discloses a prior sale by Scott Dreyer of 4,861 shares on 08/13/2025 for gross proceeds of $184,880.84. The notice includes the standard representation that the seller does not possess undisclosed material adverse information.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
